Vaccine composition

Patent metadata

Field	Value
Publication number	US-9233151-B2
Application number	US-201213439829-A
Country	US
Kind code	B2
Filing date	Apr 4, 2012
Priority date	Jun 29, 2000
Publication date	Jan 12, 2016
Grant date	Jan 12, 2016

Abstract

A multi-valent vaccine composition is described comprising a conjugate of the capsular polysaccharide of H. influenzae b not adsorbed onto an aluminum adjuvant salt, and two or more further bacterial polysaccharides. A multi-valent vaccine composition is also described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, Hepatitis B surface antigen, a conjugate of the capsular polysaccharide of H. influenzae b, and a conjugate of a capsular polysaccharide of N. meningitidis type A or C (or both). Furthermore, a multi-valent vaccine composition is described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, and a low dose of a conjugate of the capsular polysaccharide of H. influenzae b.

First claim

We claim:

1. A multivalent immunogenic composition comprising the following components:
(a) killed whole-cell Bordetella pertussis,
(b) tetanus toxoid,
(c) diphtheria toxoid,
(d) Hepatitis B surface antigen,
(e) a conjugate of a carrier protein and the capsular polysaccharide of Haemophilus influenzae type B and
(f) one or more conjugates of a carrier protein and the capsular polysaccharide of a bacterium selected from the group consisting of Neisseria meningitidis type A and N. meningitidis type C.

2. The multivalent immunogenic composition of claim 1 , wherein the composition further comprises one or more conjugates of a carrier protein and the capsular polysaccharide of a bacterium selected from the group consisting of Neisseria meningitidis type Y and N. meningitidis type W.

3. The multivalent immunogenic composition of claim 1 , wherein the capsular polysaccharide of said Haemophilus influenzae type B is conjugated to a carrier protein selected from the group consisting of tetanus toxoid, diphtheria toxoid, CRM197, outer membrane protein complex (OMPC) of N. meningitidis , and protein D of H. influenzae.

4. The multivalent immunogenic composition of claim 1 , wherein the capsular polysaccharide of said N. meningitidis is conjugated to a carrier protein selected from the group consisting of tetanus toxoid, diphtheria toxoid, CRM197, outer membrane protein complex (OMPC) of N. meningitidis , and protein D of H. influenzae.

5. The multivalent immunogenic composition of claim 1 , wherein the composition further comprises killed, attenuated Hepatitis A virus.

6. The multivalent immunogenic composition of claim 1 , wherein the composition further comprises inactivated polio virus.

7. The multivalent immunogenic composition of claim 1 , wherein the composition comprises an adjuvant.

8. The multivalent immunogenic composition of claim 7 , wherein the adjuvant is aluminium salt.

9. A method of immunizing a mammalian host, the method comprising administering to the host an immunogenic dose of the multivalent immunogenic composition of claim 1 .

10. A method of making the multivalent immunogenic composition of claim 1 comprising the step of mixing together the components (a), (b), (c), (d), (e) and (f).

Assignees

• Boutriau Dominique
• Capiau Carine
• Desmons Pierre Michel
• Lemoine Dominique
• Poolman Jan
• Glaxosmithkline Biolog Sa

Inventors

• Boutriau Dominique
• Capiau Carine
• Desmons Pierre Michel
• Lemoine Dominique
• Poolman Jan

Classifications

• A61P31/12

  Antivirals · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• A61P31/04

  Antibacterial agents · CPC title